PD-L1 expression and tumor mutation burden are the only predictive factors validated in phase III clinical trials, but are still imperfect since there are ICI non-responders expressing high biomarkers levels and ICI responders with low biomarkers levels. This evidence concerns the gene CD274 and neoplasm.